RxDoctor Payments Data

Gretchen Webb-Kummer, MD

Family Medicine · Oakdale, CANPI 1356475347

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 71 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$324
  • Pfizer$207
  • AstraZeneca$136
  • Lilly USA, LLC$76
  • Novo Nordisk$52
  • Sumitomo Pharma America, Inc.$47
  • plus $348 from 17 others

What the payments were for

  • Food & beverage$1,17399%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,190 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$90,026
Medicare patients
219
Services billed
1,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$65,814
JanuviaSitagliptin Phosphate28$31,531
JardianceEmpagliflozin29$28,225
FarxigaDapagliflozin Propanediol27$24,157
XareltoRivaroxaban28$24,068
MounjaroTirzepatide19$20,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,204
OzempicSemaglutide12$18,872
RybelsusSemaglutide16$16,407
TrulicityDulaglutide11$10,580
CreonLipase/Protease/Amylase12$7,775
BrilintaTicagrelor13$6,593
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,571
Spiriva HandihalerTiotropium Bromide13$6,390
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen238$5,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$207$65,81473 claims
Novo NordiskOzempic, Rybelsus$52$35,28028 claims
MerckJanuvia$45$31,53128 claims
Lilly USA, LLCMounjaro, Trulicity$76$30,89130 claims
AstraZenecaFarxiga, Brilinta$136$30,74940 claims
Boehringer IngelheimJardiance$16$28,22529 claims
GSKTrelegy Ellipta, Anoro Ellipta$324$25,77544 claims
AbbVieCreon$23$7,77512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Oakdale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →